Literature DB >> 21308974

Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'.

Timothy H Montague1, Diane Potvin, Charles E Diliberti, Walter W Hauck, Alan F Parr, Donald J Schuirmann.   

Abstract

In 2008, this group published a paper on approaches for two-stage crossover bioequivalence (BE) studies that allowed for the reestimation of the second-stage sample size based on the variance estimated from the first-stage results. The sequential methods considered used an assumed GMR of 0.95 as part of the method for determining power and sample size. This note adds results for an assumed GMR = 0.90. Two of the methods recommended for GMR = 0.95 in the earlier paper have some unacceptable increases in Type I error rate when the GMR is changed to 0.90. If a sponsor wants to assume 0.90 for the GMR, Method D is recommended.
Copyright © 2011 John Wiley & Sons, Ltd. Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21308974     DOI: 10.1002/pst.483

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  12 in total

1.  Futility rules in bioequivalence trials with sequential designs.

Authors:  Anders Fuglsang
Journal:  AAPS J       Date:  2013-11-12       Impact factor: 4.009

Review 2.  Two-stage designs in bioequivalence trials.

Authors:  Helmut Schütz
Journal:  Eur J Clin Pharmacol       Date:  2015-01-22       Impact factor: 2.953

3.  Pilot and Repeat Trials as Development Tools Associated with Demonstration of Bioequivalence.

Authors:  Anders Fuglsang
Journal:  AAPS J       Date:  2015-03-04       Impact factor: 4.009

4.  An insight into the properties of a two-stage design in bioequivalence studies.

Authors:  Vangelis Karalis; Panos Macheras
Journal:  Pharm Res       Date:  2013-04-09       Impact factor: 4.200

5.  Sequential bioequivalence trial designs with increased power and controlled type I error rates.

Authors:  Anders Fuglsang
Journal:  AAPS J       Date:  2013-03-30       Impact factor: 4.009

6.  Sequential bioequivalence approaches for parallel designs.

Authors:  Anders Fuglsang
Journal:  AAPS J       Date:  2014-02-14       Impact factor: 4.009

7.  A sequential bioequivalence design with a potential ethical advantage.

Authors:  Anders Fuglsang
Journal:  AAPS J       Date:  2014-05-29       Impact factor: 4.009

8.  A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs.

Authors:  Sophie I E Knahl; Benjamin Lang; Frank Fleischer; Meinhard Kieser
Journal:  Eur J Clin Pharmacol       Date:  2018-01-23       Impact factor: 2.953

9.  Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies.

Authors:  Michael J Grayling; Adrian P Mander; James M S Wason
Journal:  Stat Biopharm Res       Date:  2019-09-06       Impact factor: 1.452

10.  10th Anniversary of a Two-Stage Design in Bioequivalence. Why Has it Still Not Been Implemented?

Authors:  Michał Kaza; Alexander Sokolovskyi; Piotr J Rudzki
Journal:  Pharm Res       Date:  2020-07-13       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.